Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.

The Prostate - 1 Aug 2017

Chen Haitao, Na Rong, Packiam Vignesh T, Conran Carly A, Jiang Deke, Tao Sha, Yu Hongjie, Lin Xiaoling, Meng Wei, Zheng S Lilly, Brendler Charles B, Helfand Brian T, Xu Jianfeng

Abstract excerpt

BACKGROUND: Although the clinical validity of risk-associated single nucleotide polymorphisms (SNPs) for assessment of disease susceptibility has been consistently established, risk reclassification from increasing numbers of implicated risk-associated SNPs raises concern that it is premature for clinical use. Our objective is to assess the degree and impact of risk reclassification with the increasing number of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Polymorphism, Single Nucleotide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prostatic Neoplasms

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 28670847
DOI: 10.1002/pros.23369
PMCID: PMC6949015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.PMID 28670847Read ↗

Clinical validity and utility of genetic risk scores in prostate cancer.Semantic proximity Read ↗

Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer.Semantic proximity Read ↗

Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.Semantic proximity Read ↗

Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.Semantic proximity Read ↗

Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes.Semantic proximity Read ↗

Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.Semantic proximity Read ↗

Improved prostate cancer prediction by combining Prostate-Specific Antigen (PSA) test results with Genetic Risk Scores (GRS/PRS)Semantic proximity Read ↗

Personalized prostate cancer screening: improving PSA tests with genomic information.Semantic proximity Read ↗

Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.Semantic proximity Read ↗

A genetic risk score to guide age-specific, personalized prostate cancer screeningSemantic proximity Read ↗

A genetic-based approach to personalized prostate cancer screening and treatment.Semantic proximity Read ↗

Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.